MedTrace Logo

The Effects of Bromelain Supplement in Patients With Ulcerative Colitis

NCT06351696 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2024-04-09

No results posted yet for this study

Summary

In this study, patients with active mild to moderate UC with or without PSC will be randomized to receive either bromlein or placebo along with low FODMAP diet for 8 weeks.

IBDQ, SCCAIQ, CRP, TAC, TNF-a will be measured before and after the intervention.

Conditions

Interventions

DIETARY_SUPPLEMENT

Bromlein

1500 mg/day

OTHER

Placebo

Placebo (1500 mg/day)

Sponsors & Collaborators

  • National Nutrition and Food Technology Institute

    lead OTHER

Principal Investigators

  • Azita Hekmatdoost, MD, PhD · Shahid Beheshti University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-20
Primary Completion
2024-07-20
Completion
2024-08-10

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06351696 on ClinicalTrials.gov